These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 27469899)

  • 1. Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease.
    Vionnet J; Saouli AC; Pascual M; Stucker F; Decosterd LA; Moradpour D; Chtioui H
    J Hepatol; 2016 Nov; 65(5):1063-1065. PubMed ID: 27469899
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to: "Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease".
    Desnoyer A; Lê MP; Yazdanpanah Y; Peytavin G;
    J Hepatol; 2016 Nov; 65(5):1065-1066. PubMed ID: 27460834
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients.
    Huang H; Tang H; Deng H; Shen J; Zhou Q; Xie W; Wu J; Chen J
    Transpl Infect Dis; 2019 Feb; 21(1):e13018. PubMed ID: 30369001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients.
    Schrezenmeier E; Hoffmann F; Jaeger C; Schrezenmeier J; Lisec J; Glander P; Algharably E; Kreutz R; Budde K; Duerr M; Halleck F
    Ther Drug Monit; 2019 Feb; 41(1):53-58. PubMed ID: 30422962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness and safety of sofosbuvir+daclatasvir in the treatment of chronic hepatitis C virus infection in Yan'an, Shaanxi].
    Gao XH; Jing P
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jun; 27(6):457-459. PubMed ID: 31357763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection.
    Xue Y; Zhang LX; Wang L; Li T; Qu YD; Liu F
    World J Gastroenterol; 2017 Aug; 23(32):5969-5976. PubMed ID: 28932089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.
    Teegen EM; Globke B; Schott E; Pratschke J; Eurich D
    Exp Clin Transplant; 2018 Feb; 16(1):61-67. PubMed ID: 29137590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
    Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
    Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sofosbuvir plus daclatasvir as an alternative for patients on haemodialysis with genotype 2 hepatitis C virus infection.
    Llenas-García J; Padilla S; Masiá M; Gutiérrez F
    Enferm Infecc Microbiol Clin (Engl Ed); 2018; 36(7):457. PubMed ID: 29217095
    [No Abstract]   [Full Text] [Related]  

  • 10. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
    Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
    Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Daclatasvir-sofosbuvir combination therapy for chronic hepatitis C virus infection: progress in clinical studies].
    Lu J; Zhou HJ; Xie Q
    Zhonghua Gan Zang Bing Za Zhi; 2018 Feb; 26(2):147-150. PubMed ID: 29804384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of HCV-related glomerulonephritis with sofosbuvir and daclatasvir.
    Chia XX; Cherepanoff S; Danta M; Furlong T
    Nephrology (Carlton); 2018 Apr; 23(4):379-380. PubMed ID: 29520905
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
    Campos-Varela I; Moreno A; Morbey A; Guaraldi G; Hasson H; Bhamidimarri KR; Castells L; Grewal P; Baños I; Bellot P; Brainard DM; McHutchison JG; Terrault NA
    Aliment Pharmacol Ther; 2016 Jun; 43(12):1319-29. PubMed ID: 27098374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
    Castedal M; Segenmark M; Cederberg S; Skoglund C; Weiland O
    Scand J Gastroenterol; 2017 May; 52(5):585-588. PubMed ID: 28270038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late.
    Pellicelli AM; Montalbano M; Lionetti R; Durand C; Ferenci P; D'Offizi G; Knop V; Telese A; Lenci I; Andreoli A; Zeuzem S; Angelico M
    Dig Liver Dis; 2014 Oct; 46(10):923-7. PubMed ID: 24997638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daclatasvir: A Review in Chronic Hepatitis C.
    Keating GM
    Drugs; 2016 Sep; 76(14):1381-91. PubMed ID: 27550544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection.
    Sundaram V; Kowdley KV
    Expert Rev Gastroenterol Hepatol; 2016; 10(1):13-20. PubMed ID: 26560449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir plus daclatasvir with or without ribavirin for chronic hepatitis C infection: Impact of drug concentration on viral load decay.
    Virlogeux V; Choupeaux L; Pradat P; Maynard M; Bailly F; Scholtès C; Gagnieu MC; Zoulim F
    Dig Liver Dis; 2016 Nov; 48(11):1351-1356. PubMed ID: 27498075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients.
    Saab S; Greenberg A; Li E; Bau SN; Durazo F; El-Kabany M; Han S; Busuttil RW
    Liver Int; 2015 Nov; 35(11):2442-7. PubMed ID: 25913321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.